Locally Advanced Rectal Cancer clinical trials

Explore recruiting locally advanced rectal cancer clinical trials.

Recruiting locally advanced rectal cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Rectal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high risk (“ugly”) locally advanced rectal cancer.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer: the ShorTrip trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentre, open-label, randomised, controlled, parallel-arms, phase III, clinical trial of Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer: MEND-IT II

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Locally Advanced Rectal Cancer trials by city

Locally Advanced Rectal Cancer in Toronto Locally Advanced Rectal Cancer in Vancouver Locally Advanced Rectal Cancer in Montreal Locally Advanced Rectal Cancer in Calgary Locally Advanced Rectal Cancer in Edmonton Locally Advanced Rectal Cancer in Ottawa Locally Advanced Rectal Cancer in Winnipeg Locally Advanced Rectal Cancer in Quebec City Locally Advanced Rectal Cancer in Hamilton Locally Advanced Rectal Cancer in Kitchener Locally Advanced Rectal Cancer in London Locally Advanced Rectal Cancer in Halifax Locally Advanced Rectal Cancer in New York Locally Advanced Rectal Cancer in Los Angeles Locally Advanced Rectal Cancer in Chicago Locally Advanced Rectal Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease